Metabolon Expands Service Offerings With Launch Of mProveClinical(TM) For First-in-Human Studies

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery, today introduced mProveClinical™, a service offering that provides insight into a drug’s biochemical and physiological effects in first-in-human clinical trials. Combined with clinical observations and measurements, mProveClinical provides drug development organizations with key information on a subject’s response to a drug. This data enables more informed decisions to be made about the drug’s continued testing and positioning or, if required, offers guidance as to how it can be repositioned.

Back to news